As per the current market research conducted by the CMI Team, the global Sacral Neuromodulation Market size is expected to record a CAGR of 6.35% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 426 Million. By 2033, the valuation is anticipated to reach USD 741.39 Million.
Sacral Neuromodulation Market: Growth Factors and Dynamics
- Increasing Consumer Demand for Non-Invasive Treatments: There is a growing preference among patients for non-invasive and minimally invasive medical treatments. Sacral neuromodulation offers an effective solution for managing conditions like urinary and fecal incontinence with less surgical intervention, driving its popularity.
- Rising Prevalence of Pelvic Disorders: The global rise in pelvic disorders, including urinary incontinence and chronic pelvic pain, boosts the market for sacral neuromodulation. This technology provides a therapeutic option for conditions often difficult to manage with conventional treatments.
- Technological Advancements: Continuous innovations in neuromodulation technology, including the development of smaller, more efficient implantable devices and wireless control systems, enhance the performance and user experience of sacral neuromodulation, attracting both patients and healthcare providers.
- Expansion of Healthcare Infrastructure: The expansion of healthcare infrastructure worldwide drives the demand for advanced therapeutic solutions like sacral neuromodulation. Hospitals, specialty clinics, and ambulatory surgical centers increasingly adopt this technology to improve patient outcomes and expand their treatment offerings.
- Growth in Geriatric Population: The increasing trend of an aging population, which is more prone to conditions like incontinence, propels the market for sacral neuromodulation. Older adults seek effective and sustainable treatment options to maintain their quality of life, driving demand for these devices.
- Health and Wellness Trends: Growing health and wellness awareness supports market growth for sacral neuromodulation devices that offer improved management of chronic conditions with minimal side effects. Patients are increasingly opting for therapies that enhance their overall well-being and lifestyle.
Sacral Neuromodulation Market: New Acquisitions and Product Launch
- In January 2024, Boston Scientific announced the acquisition of Axonics for $37 million. This strategic move aims to enhance Boston Scientific’s portfolio in the incontinence treatment market, leveraging Axonics’ innovative sacral neuromodulation technologies. The acquisition underscores Boston Scientific’s commitment to expanding its offerings and addressing the growing demand for effective incontinence treatments.
- In April 2023, Axonics announced the acquisition of new technology designed to facilitate easier and faster placement of implantable leads for sacral neuromodulation. This advancement aims to improve the efficiency and effectiveness of sacral neuromodulation procedures, enhancing patient outcomes and expanding Axonics’ capabilities in treating bladder and bowel dysfunction. The acquisition underscores Axonics’ commitment to innovation and continuous improvement in neuromodulation technologies.
- In December 2022, a new recharge-free sacral neuromodulation system for bladder and bowel dysfunction was launched in the US market. This innovative system aims to provide patients with a hassle-free solution for managing their conditions without the need for regular recharging. The launch marks a significant advancement in the treatment of bladder and bowel dysfunction, offering enhanced convenience and improved quality of life for patients.
Report Scope
Feature of the Report | Details |
Market Size in 2024 | USD 426 Million |
Projected Market Size in 2033 | USD 741.39 Million |
Market Size in 2023 | USD 410.44 Million |
CAGR Growth Rate | 6.35% CAGR |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Key Segment | By Application, Product, Technology, End Use and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Sacral Neuromodulation Market: COVID-19 Analysis
The COVID-19 pandemic has significantly impacted the Sacral Neuromodulation Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:
- Disruption in International Trade and Businesses: The ongoing COVID-19 pandemic has disrupted international trade and businesses, significantly affecting the Sacral Neuromodulation Market. Government-imposed restrictions on the transit of people and goods have led to supply chain and manufacturing disruptions, impacting the production and distribution of sacral neuromodulation devices.
- Demand Fluctuations: The pandemic caused disruptions in healthcare services, including elective surgeries and non-emergency procedures. Lockdown measures, supply chain disruptions, and reduced hospital visits resulted in a slowdown in the adoption of sacral neuromodulation devices. Many ongoing and planned medical procedures were delayed or put on hold due to the uncertainties surrounding the pandemic.
- Regulatory Framework and Market Restraints: The regulatory framework for sacral neuromodulation devices has been influenced by the pandemic, with potential changes in safety standards and regulations affecting market operations. Economic uncertainties have posed challenges such as high costs, technical limitations, and a lack of skilled workforce, restraining market growth.
- Operational Challenges: Implementing health and safety protocols in manufacturing facilities added operational challenges and increased production costs. Labor shortages and workforce disruptions, including illness-related absences and quarantine measures, affected production capacities and efficiency in the Sacral Neuromodulation Market.
- Adaptive Strategies and Focus on Innovation: Companies adopted remote work arrangements, digitalized sales and marketing efforts, and diversified supply chain sources to mitigate the pandemic’s impact. Some firms directed efforts towards innovating sacral neuromodulation devices, integrating advanced features like wireless control and rechargeable batteries to cater to evolving healthcare needs.
- Technological Advancements: Ongoing advancements in neuromodulation technology, such as improved electrode design, enhanced programming capabilities, and better patient interface, are opening doors to new applications and expanding the market potential for sacral neuromodulation. These innovations aim to improve patient outcomes and device performance.
- Automation Push: The pandemic highlighted the importance of automation in manufacturing and healthcare environments to minimize reliance on human labor. This could lead to an increase in demand for automated systems within sacral neuromodulation, ensuring continuous and reliable patient care.
- Focus on Sustainability: The market is also seeing a growing emphasis on sustainability, with manufacturers developing eco-friendly models that use less energy and reduce waste. This trend aligns with the increasing awareness and demand for environmentally responsible healthcare solutions.
In conclusion, the COVID-19 pandemic has had a mixed impact on the Sacral Neuromodulation Market, with some challenges and opportunities arising from the pandemic.
List of the prominent players in the Sacral Neuromodulation Market:
- Medtronic plc
- Axonics Modulation Technologies Inc.
- Boston Scientific Corporation
- Abbott Laboratories
- Laborie Medical Technologies
- Cogentix Medical Inc.
- Cyberonics Inc.
- Nuvectra Corporation
- Nevro Corp.
- Synapse Biomedical Inc.
- ImThera Medical Inc.
- BioControl Medical
- Advanced Bionics AG
- Stryker Corporation
- Inspire Medical Systems Inc.
- Uroplasty Inc.
- EndoStim Inc.
- Brainsway Ltd.
- MicroTransponder Inc.
- Stimwave LLC
- Others
The Sacral Neuromodulation Market is segmented as follows:
By Application
- Urinary Incontinence
- Fecal Incontinence
- Chronic Pelvic Pain
- Others
By Product
- Implantable Devices
- External Devices
- Accessories
By Technology
- Conventional Sacral Neuromodulation
- Rechargeable Sacral Neuromodulation
- Wireless Sacral Neuromodulation
By End Use
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America